• S2 Ep8: The FDA Decision for Pompe Disease Therapy

  • Oct 28 2022
  • Length: 13 mins
  • Podcast

S2 Ep8: The FDA Decision for Pompe Disease Therapy

Listen for free

View show details

  • Summary

  • The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about S2 Ep8: The FDA Decision for Pompe Disease Therapy

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available